Company
Ahead Together
We unite science, technology and talent to get ahead of disease together.
Purpose, strategy and culture
Getting ahead of disease is one of the greatest, most inspiring challenges there is on the planet. By pursuing this purpose together, we have the scale and expertise to positively impact the health of 2.5 billion people by the end of the decade. In doing so, we will deliver stronger and more sustainable growth as a company where people can thrive.
At a glance
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.
View our policy positions
We have policies in place across GSK to ensure we meet the high standards we set ourselves as a company, and those that are expected of us externally.
Learn more about our views and our practices across a range of issues that are important to GSK, our patients and our stakeholders.
Latest press releases
- Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
- Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
- US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
